Literature DB >> 3753814

Goitre size and outcome of medical treatment of Graves' disease.

P Laurberg, P E Buchholtz Hansen, E Iversen, S Eskjaer Jensen, J Weeke.   

Abstract

One hundred and twenty-four patients with newly diagnosed hyperthyroidism received a combined thionamid-thyroxine medical therapy for approximately 2 years. According to the estimated goitre size before therapy and the type of goitre the patients were divided into 4 groups: Graves' disease no goitre (n = 19), Graves' disease small goitre (n = 57), Graves' disease medium or large goitre (n = 23), multinodular goitre (n = 25). The median follow-up period after cessation of medication was 64 (range 11-141) months. The remission rates in the different groups during follow-up were calculated using life table analysis. Graves' patients with no goitre or a small goitre had a significantly better outcome (remission % after 5 years 82.5 +/- 15.4 (SE) and 71.5 +/- 7.8, respectively) than Graves' patients with a medium size or large goitre (remission % after 5 years 37.0 +/- 11.1)(P less than 0.025). Most patients with multinodular goitre had a relapse within the first year after stop of medication (remission % after 5 years 15.5 +/- 10.1). Hence patients with Graves' disease having a small thyroid gland should be treated medically while surgery or radioiodine may be a more reasonable choice in Graves' patients with medium size or large goitres. Medically treated patients with toxic multinodular goitres have a very small chance of prolonged remission if medication is stopped.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3753814     DOI: 10.1530/acta.0.1110039

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  15 in total

1.  Association study of autoimmune thyroid disease at 5q23-q33 in Japanese patients.

Authors:  Takashi Akamizu; Hitomi Hiratani; Satoshi Ikegami; Stephen S Rich; Donald W Bowden
Journal:  J Hum Genet       Date:  2003-04-09       Impact factor: 3.172

Review 2.  Hyperthyroidism (primary).

Authors:  Birte Nygaard
Journal:  BMJ Clin Evid       Date:  2010-07-19

3.  Regression of Ophthalmopathic Exophthalmos in Graves' Disease After Total Thyroidectomy: a Prospective Study of a Surgical Series.

Authors:  P R K Bhargav; M Sabaretnam; S Chandra Kumar; S Zwalitha; N Vimala Devi
Journal:  Indian J Surg       Date:  2016-06-22       Impact factor: 0.656

4.  The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study.

Authors:  L Bartalena; E Masiello; F Magri; G Veronesi; E Bianconi; F Zerbini; M Gaiti; E Spreafico; D Gallo; P Premoli; E Piantanida; M L Tanda; M Ferrario; P Vitti; L Chiovato
Journal:  J Endocrinol Invest       Date:  2016-07-27       Impact factor: 4.256

5.  [Drug treatment of immune hyperthyroidism (Basedow disease). Patient selection, long-term follow-up and prevention of recurrence].

Authors:  B Quadbeck; R Hörmann; O E Janssen; K Mann
Journal:  Internist (Berl)       Date:  2003-04       Impact factor: 0.743

6.  [Surgical therapeutic concept of immune thyropathy].

Authors:  H Dralle; O Schober; R D Hesch
Journal:  Langenbecks Arch Chir       Date:  1987

Review 7.  Hyperthyroidism (primary).

Authors:  Birte Nygaard
Journal:  BMJ Clin Evid       Date:  2008-03-25

8.  Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves' disease.

Authors:  M J van Soestbergen; J C van der Vijver; A D Graafland
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

9.  Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.

Authors:  R V García-Mayor; C Páramo; R Luna Cano; L F Pérez Mendez; J C Galofré; A Andrade
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

10.  Graves' disease: immunological and immunogenetic indicators of relapse.

Authors:  T W de Bruin; J H Bolk; J K Bussemaker; T Stijnen; G M Schreuder; R R de Vries; D van der Heide
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.